Literature DB >> 20381955

Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11).

Susan J Zunino1, David H Storms, Jonathan M Ducore.   

Abstract

Acute lymphoblastic leukemia (ALL) with translocation t(4;11) is found in 60-85% of infants with ALL and is often refractory to conventional chemotherapeutics after relapse. Using the t(4;11) ALL line SEM, we evaluated chemotherapy resistance in NOD.CB17-Prkdcscid/J mice. SEM cells were injected into the tail vein and engraftment was monitored by flow cytometry. Once engraftment was observed, mice were injected intraperitoneally with phosphate-buffered saline (PBS), or vincristine (0.5mg/kg body weight) three times per week for 4weeks (n=8 per group). The level of P-glycoprotein in SEM cells was increased 3-fold by vincristine treatment compared to PBS-treated mice. Survival curves showed that leukemia cell growth was initially delayed by vincristine treatment, but the mice eventually succumbed to disease. These data describe a novel inducible model for investigating multi-drug resistance mechanisms in high-risk t(4;11) ALL. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20381955      PMCID: PMC2906616          DOI: 10.1016/j.canlet.2010.03.017

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  25 in total

1.  The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children's Oncology Group.

Authors:  Douglas P Olson; Barbara J Taylor; Mei La; Harland Sather; Gregory H Reaman; S Percy Ivy
Journal:  Leuk Lymphoma       Date:  2005-05

Review 2.  The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia.

Authors:  M M van den Heuvel-Eibrink; P Sonneveld; R Pieters
Journal:  Int J Clin Pharmacol Ther       Date:  2000-03       Impact factor: 1.366

3.  The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse.

Authors:  Richard B Lock; Natalia Liem; Monica L Farnsworth; Christopher G Milross; Chengyuan Xue; Mayamin Tajbakhsh; Michelle Haber; Murray D Norris; Glenn M Marshall; Alison M Rice
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

4.  Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice.

Authors:  A Borgmann; C Baldy; A von Stackelberg; B Beyermann; I Fichtner; P Nürnberg; G Henze
Journal:  Pediatr Hematol Oncol       Date:  2000-12       Impact factor: 1.969

5.  The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein.

Authors:  K Ueda; M M Cornwell; M M Gottesman; I Pastan; I B Roninson; V Ling; J R Riordan
Journal:  Biochem Biophys Res Commun       Date:  1986-12-30       Impact factor: 3.575

6.  Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies.

Authors:  Natalia L M Liem; Rachael A Papa; Christopher G Milross; Michael A Schmid; Mayamin Tajbakhsh; Seoyeon Choi; Carole D Ramirez; Alison M Rice; Michelle Haber; Murray D Norris; Karen L MacKenzie; Richard B Lock
Journal:  Blood       Date:  2004-02-05       Impact factor: 22.113

7.  Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.

Authors:  J B Nachman; H N Sather; M G Sensel; M E Trigg; J M Cherlow; J N Lukens; L Wolff; F M Uckun; P S Gaynon
Journal:  N Engl J Med       Date:  1998-06-04       Impact factor: 91.245

8.  High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukaemic cells in adults than in children.

Authors:  Sabine L A Plasschaert; Edo Vellenga; Eveline S J M de Bont; Dorina M van der Kolk; Anjo J P Veerman; Wim J Sluiter; Simon M G Daenen; Elisabeth G E de Vries; Willem A Kamps
Journal:  Leuk Lymphoma       Date:  2003-01

Review 9.  Central and peripheral nervous system toxicity of common chemotherapeutic agents.

Authors:  Chrissa Sioka; Athanassios P Kyritsis
Journal:  Cancer Chemother Pharmacol       Date:  2008-11-25       Impact factor: 3.333

10.  Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.

Authors:  A B Hill; W T Beck; J M Trent
Journal:  Cancer Res       Date:  1988-01-15       Impact factor: 12.701

View more
  5 in total

1.  Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.

Authors:  Daniel Nowak; Natalia L M Liem; Maximilian Mossner; Marion Klaumünzer; Rachael A Papa; Verena Nowak; Johann C Jann; Tadayuki Akagi; Norihiko Kawamata; Ryoko Okamoto; Nils H Thoennissen; Motohiro Kato; Masashi Sanada; Wolf-Karsten Hofmann; Seishi Ogawa; Glenn M Marshall; Richard B Lock; H Phillip Koeffler
Journal:  Exp Hematol       Date:  2014-10-29       Impact factor: 3.084

2.  Oral or parenteral administration of curcumin does not prevent the growth of high-risk t(4;11) acute lymphoblastic leukemia cells engrafted into a NOD/SCID mouse model.

Authors:  Susan J Zunino; David H Storms; John W Newman; Theresa L Pedersen; Carl L Keen; Jonathan M Ducore
Journal:  Int J Oncol       Date:  2012-12-12       Impact factor: 5.650

3.  Resveratrol given intraperitoneally does not inhibit the growth of high-risk t(4;11) acute lymphoblastic leukemia cells in a NOD/SCID mouse model.

Authors:  Susan J Zunino; David H Storms; John W Newman; Theresa L Pedersen; Carl L Keen; Jonathan M Ducore
Journal:  Int J Oncol       Date:  2011-12-22       Impact factor: 5.650

4.  Dietary resveratrol does not delay engraftment, sensitize to vincristine or inhibit growth of high-risk acute lymphoblastic leukemia cells in NOD/SCID mice.

Authors:  Susan J Zunino; David H Storms; John W Newman; Theresa L Pedersen; Carl L Keen; Jonathan M Ducore
Journal:  Int J Oncol       Date:  2012-10-04       Impact factor: 5.650

5.  Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia.

Authors:  Babasaheb D Yadav; Amy L Samuels; Julia E Wells; Rosemary Sutton; Nicola C Venn; Katerina Bendak; Denise Anderson; Glenn M Marshall; Catherine H Cole; Alex H Beesley; Ursula R Kees; Richard B Lock
Journal:  Oncotarget       Date:  2016-09-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.